耐火性EBV阳性DLBCL的PD-1抑制剂加上化疗:回顾性分析
Youli Li1,2, Yonghe Wu3, Sufen Cao1,4
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P.R. China.
Blood research
|October 30, 2024
概括
与化疗相结合的PD-1抑制剂对耐火性爱斯坦-巴尔病毒阳性扩散性大B细胞淋巴瘤 (EBV+DLBCL) 有希望. 这种方法在一小群患者中产生了高响应率和可控的副作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 免疫化疗对B细胞淋巴瘤有效,但对EBV+DLBCL有限.
- 耐药/复发性EBV+DLBCL在标准治疗中表现不佳.
- 在EBV+DLBCL中较高的PD-L1表达表明PD-1阻塞的可能性.
研究的目的:
- 评估PD-1抑制剂加上化疗作为耐火性EBV+DLBCL的二线治疗的疗效和安全性.
主要方法:
- 对六名耐火性EBV+DLBCL的成年患者进行了回顾性研究.
- 患者在R-CHOP失败后接受了PD-1抑制剂与化疗相结合的二线治疗.
主要成果:
- 客观反应率为83% (5/6);完全缓解率为67% (4/6).
- 随访时间中位数为20个月.
- 没有严重的免疫相关不良事件;只报告了轻微的皮疹.
结论:
- PD-1 抑制剂加上化疗证明了耐火性EBV+ DLBCL的有希望的疗效和安全性.
- 这种组合可能是有效的二线治疗选择.
- 需要进一步的大规模临床试验来证实这些发现.
更多相关视频
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.7K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
相关概念视频
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
